|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/56 | (2006.01) |
| (11) | Number of the document | 2712617 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13189553.4 |
| Date of filing the European patent application | 2005-03-14 | |
| (97) | Date of publication of the European application | 2014-04-02 |
| (45) | Date of publication and mention of the grant of the patent | 2016-11-02 |
| (46) | Date of publication of the claims translation | 2017-01-25 |
| (30) | Number | Date | Country code |
| 552865 P | 2004-03-12 | US |
| (72) |
Fiorucci, Stefano, IT
Pelliciari, Roberto, IT
Pruzanski, Mark, US
|
| (73) |
Intercept Pharmaceuticals, Inc.,
421 Hudson Street, Suite 212, New York, NY 10014,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Fibrozės gydymas, naudojant FXR ligandus |
| Treatment of fibrosis using Fxr ligands |
| Payment date | Validity (years) | Amount | |
| 2021-02-18 | 17 | 347.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2022-03-14 |